(Q34139923)

31 July 2017

title

Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary (English)

1 reference

31 July 2017

Vascular Endothelial Growth Factor Is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the Ovary (English)

1 reference

Crossref

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0169

11 June 2024

0 references

1 reference

14

Tadashi Kimura

1 reference

31 July 2017

1

Seiji Mabuchi

1 reference

31 July 2017

Ken-ichirou Morishige

4

object named as

Kenichirou Morishige

1 reference

31 July 2017

2

Chiaki Kawase

1 reference

31 July 2017

3

Deborah A Altomare

1 reference

31 July 2017

6

Kenjiro Sawada

1 reference

31 July 2017

7

Kimihiko Ito

1 reference

31 July 2017

9

Yukihiro Nishio

1 reference

31 July 2017

Andres J Klein-Szanto

10

object named as

Andres J Klein-Szanto

1 reference

31 July 2017

12

Masahide Ohmichi

1 reference

31 July 2017

13

Joseph R Testa

1 reference

31 July 2017

Masami Hayashi

5

1 reference

31 July 2017

Yoshito Terai

8

1 reference

31 July 2017

Kenichirou Morishige

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20663925

11 June 2024

Robert A. Burger

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20663925

11 June 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20663925

11 June 2024

publication date

27 July 2010

1 reference

full work available at URL

31 July 2017

https://mct.aacrjournals.org/content/molcanther/9/8/2411.full.pdf

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20663925

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20663925/?tool=EBI

11 June 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20663925

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20663925/pdf/?tool=EBI

11 June 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20663925

http://intl-mct.aacrjournals.org/cgi/content/abstract/9/8/2411

11 June 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20663925

https://europepmc.org/articles/PMC2941981

11 June 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20663925

https://europepmc.org/articles/PMC2941981?pdf=render

11 June 2024

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20663925

https://doi.org/10.1158/1535-7163.mct-10-0169

11 June 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20663925

https://aacrjournals.org/mct/article-pdf/9/8/2411/1888212/2411.pdf

11 June 2024

1 reference

Crossref

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0169

Molecular Cancer Therapeutics

11 June 2024

published in

1 reference

31 July 2017

volume

9

1 reference

31 July 2017

issue

8

1 reference

31 July 2017

page(s)

2411-2422

1 reference

mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

Theoretical model of treatment strategies for clear cell carcinoma of the ovary: focus on perspectives

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

Prognostic implication of endometriosis in clear cell carcinoma of the ovary

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

Angiogenic effect of naive and 5-fluorouracil resistant colon carcinoma on endothelial cells in vitro

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

The management of recurrent ovarian cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

Antiproliferative effects of interferon-alphaCon1 on ovarian clear cell adenocarcinoma in vitro and in vivo

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

A novel retinoid, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), induces apoptosis of human ovarian carcinoma cells and shows potential as a new antitumor agent for clear cell adenocarcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

Selective inhibition of the epidermal growth factor receptor by ZD1839 decreases the growth and invasion of ovarian clear cell adenocarcinoma cells.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

Hypoxia--a key regulatory factor in tumour growth

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

Recent progress in ovarian cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

How well do angiogenesis inhibitors work? Biomarkers of response prove elusive.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2941981

Changes in VEGF level and tumor growth characteristics during lewis lung carcinoma progression towards cis-DDP resistance

28 October 2018

1 reference

12 December 2020

Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma

1 reference

12 December 2020

VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer

1 reference

12 December 2020

Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues

1 reference

12 December 2020

Antitumour activity of cis-diamminedichloroplatinum (II) against human tumour xenografts depends on its area under the curve in nude mice

1 reference

12 December 2020

Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease

1 reference

12 December 2020

Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer

1 reference

12 December 2020

Activation of mammalian target of rapamycin in postmenopausal ovarian endometriosis

1 reference

12 December 2020

Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo

1 reference

12 December 2020

Mesonephroma ovarii

34

1 reference

Crossref

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0169

11 June 2024

Identifiers

1 reference

31 July 2017

1 reference

31 July 2017

1 reference